IND filing preparation

Dauntless Biotherapeutics is a private preclinical oncology company led and advised by a team of researchers and industry veterans. It is developing an Antibody Drug Conjugate (ADC) to an undisclosed Tumor Associated Antigen (TAA) to treat cancers of unmet need, and is conducting a seed round to raise capital for lead optimization, in vivo, and non-GLP toxicity studies in preparation of an IND filing.

Read more

in vivo studieslead optimizationnon-GLP toxicity studies